Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspiration Hlt Regulatory News (IHC)

Share Price Information for Inspiration Hlt (IHC)

Share Price is delayed by 15 minutes
Get Live Data
22.50    0.00 (0.00%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £20.17m
IHC Live PriceLast checked at - London Stock Exchange

Intraday Inspiration Hlt Share Chart

Project Wave- IRAS submission

8 Sep 2020 07:00

RNS Number : 2736Y
Inspiration Healthcare Group PLC
08 September 2020
 

Inspiration Healthcare Group plc

 ("Inspiration Healthcare", the "Company" or the "Group")

 

Project WAVE - IRAS submission

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company is pleased to announce that it has submitted an application through the Integrated Research Approval System (IRAS) for trials to begin for the respiratory device it has designed for use in neonatal intensive care known as Project WAVE. The technology for Project WAVE was acquired by Inspiration Healthcare under licence in 2018 from a leading U.S. West Coast University and was granted a patent by the U.S. Patent Office as was announced on 25 March 2020.

 

The IRAS submission requests permission for the trial to begin at the Trevor Mann Baby Unit, Brighton & Sussex University Hospital (Royal Sussex). The application will be reviewed by The Medicines and Healthcare products Regulatory Agency (MRHA), Research Ethics Committee (REC) and Health Research Authority (HRA) to allow a non-C.E. marked device to be used under trial conditions.

 

Project WAVE received a grant towards the cost of this trial under the Med Tech Trials Innovation Support Grant scheme (MTT-ISG), awarded on 11 June 2020 by the Academic Health Science Networks (AHSN). The MTT-ISG grant is funded by the European Regional Development Fund (ERDF) who will contribute up to 50% (£50,000 maximum) towards the costs of this trial.

 

Neil Campbell, Chief Executive Officer, commented: "We are pleased to have submitted this application and moving the project on to the next phase. The Project WAVE device we have developed incorporates the latest findings in neonatal respiration from a leading U.S. West Coast University with Inspiration Healthcare's experience and knowledge in designing and manufacturing neonatal devices which improve medical outcomes. Once our submission gets the green light, which we expect in a few months, we look forward to working with the team at the Royal Sussex and getting the project one step closer to fruition."

 

 

 

Enquiries:

 

Inspiration Healthcare Group plc

Neil Campbell, Chief Executive Officer

Jon Ballard, Chief Financial Officer

Tel: 01455 840555

 

Nominated Adviser & Broker

Cenkos Securities plc

Mark Connelly

Stephen Keys

Cameron MacRitchie

Tel: 0207 397 8900

 

Cadogan PR

Alex Walters

alex.walters@cadoganpr.com

Tel: 07771 713608

 

 

About Inspiration Healthcare http://www.inspiration-healthcare.com

 

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high-quality, innovative products to patients around the world which help to improve patient outcomes, and it actively invests in innovative product opportunities and disruptive technologies.

Through investment in research and development the Company has six key own-brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally, the Company has a range of products for maintaining normothermia pre- during and post-surgery.

In September 2019, the Company acquired Vio Holdings a designer, manufacturer and supplier of single-use respiratory products and sterile medical consumables for £4 million and in June 2020 the Company acquired SLE, a leading global provider of neonatal ventilation products for £18 million.   Over 90% of SLE's revenues are generated from sales outside of the UK with a significant proportion of these in the Asia Pacific and the Middle East. When combined, the Group generates approximately 60 per cent. of its revenue from exports.

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the .K.U.K. and Ireland, the Company has a direct sales team selling Inspiration Healthcare Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

Further information on Inspiration Healthcare can be seen at www.inspiration-healthcare.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAZZGGLVNVGGZM
Date   Source Headline
16th Jun 20267:00 amRNSFinal Results
2nd Jun 20267:01 amRNSNotice of Results
2nd Jun 20267:00 amRNSTransfer of Non-Core Products to Focus on Neonatal
14th Apr 20267:00 amRNSChange of Adviser
16th Mar 20269:33 amRNSHolding(s) in Company
16th Mar 20269:33 amRNSHolding(s) in Company
5th Mar 20267:00 amRNSUK neonatal division wins NHS framework agreement
26th Feb 20269:23 amRNSHolding(s) in Company
12th Feb 20267:00 amRNSFull year trading update
10th Feb 20269:05 amRNSHolding(s) in Company
3rd Feb 20267:00 amRNSAppointment of Joint Broker
2nd Feb 202611:01 amRNSHolding(s) in Company
28th Jan 20261:40 pmRNSHolding(s) in Company
28th Jan 20267:00 amRNSPurchasing agreement in the US
27th Jan 20269:46 amRNSHolding(s) in Company
26th Jan 202610:02 amRNSHolding(s) in Company
22nd Jan 20261:37 pmRNSHolding(s) in Company
26th Nov 20257:00 amRNSChange of auditor
16th Oct 20251:51 pmRNSHolding(s) in Company
7th Oct 20257:00 amRNSHalf-year Report
23rd Sep 20257:00 amRNSResults presentations for analysts and investors
19th Sep 20257:00 amRNSDirectorate Change
20th Aug 20257:00 amRNSTrading update and notice of results
24th Jul 20251:37 pmRNSResult of AGM
24th Jul 20257:00 amRNSAGM Statement
13th Jun 20259:16 amRNSPublication of AR, accounts & notice of AGM
6th Jun 20257:00 amRNSBoard Change
28th May 20257:00 amRNSUnaudited Preliminary results
23rd May 20257:00 amRNSNotice of Results
15th May 20255:01 pmRNSHolding(s) in Company
15th May 202510:06 amRNSHolding(s) in Company
1st Apr 202511:36 amRNSHolding(s) in Company
21st Mar 20252:49 pmRNSGrant of Options
12th Mar 20256:01 pmRNSHolding(s) in Company
12th Mar 20256:00 pmRNSDirector/PDMR Shareholding
24th Feb 20254:16 pmRNSDirector/PDMR Shareholding
21st Feb 20252:52 pmRNSDirector/PDMR Shareholding
18th Feb 20257:00 amRNSTrading update
10th Feb 20259:54 amRNSHolding(s) in Company
28th Jan 20257:00 amRNSDirectorate Change
14th Jan 20254:08 pmRNSHolding(s) in Company
12th Dec 20247:00 amRNSAppointment of Chief Executive Officer
14th Nov 20247:00 amRNSBoard Change
4th Nov 20247:00 amRNSGrant of Covenant Waiver and Covenant Reset
2nd Oct 20247:00 amRNSHalf-year Report
17th Sep 202412:26 pmRNSResult of AGM
3rd Sep 20247:00 amRNSTrading update for the six months to 31 July 2024
5th Aug 20243:41 pmRNSHolding(s) in Company
2nd Aug 20247:00 amRNSNominated adviser and broker
31st Jul 20243:29 pmRNSPublication of Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.